Schizophreniform Disorders

4

Review clinical trials related to Schizophreniform Disorders. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Bazedoxifene -Treatment for Women With Schizophrenia

To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.

Participants needed: 160
Trial details
Phase: Phase 4Age: 18-65Biological sex: FemaleType: InterventionalSponsor: The AlfredUpdated: Jun 3, 2026Locations: 1
Eligibility criteria

Physically well. [+9]

Patients with known abnormalities in the hypothalamo-pituitary gonadal axis, thy... [+7]

Status: Not yet recruiting

REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

The purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. The investigators are especially interested in learning whether the Clubhouse Model-a structured, supportive community for individuals with mental illness-has unique benefits compared to standard outpatient mental health services. If participants decide to join, they will be asked to complete a total of six study visits with the research team over the course of your participation. Three of these study visits are at the beginning (baseline) and the remaining three are six months later. Two of the three visits will includes interviews, questionnaires, and thinking and memory tasks (cognitive testing) and one session will be an MRI brain scan, which is a safe and non-invasive imaging procedure. The total time required for each visit will be approximately 90 minutes to two hours. Participants may take breaks as needed.

Participants needed: 30
Trial details
Age: 18-50Biological sex: AllType: InterventionalSponsor: Case Western Reserve UniversityUpdated: Apr 27, 2026Locations: 1
Eligibility criteria

(1) have a DSM-V diagnosis of schizophrenia, schizoaffective disorder, or schizo... [+4]

(1) had previous membership at a Clubhouse (Magnolia or elsewhere) [+7]

Status: Not yet recruiting

Shared Decision Making for Antipsychotic Medications

This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the first time, an understanding of the shared decision making mechanism of action.

Participants needed: 120
Trial details
Age: 18-30Biological sex: AllType: InterventionalSponsor: New York State Psychiatric InstituteUpdated: Mar 30, 2026
Eligibility criteria

Ages 18 to 30 who have experienced nonaffective psychosis with a diagnosis of sc... [+2]

Unable to provide informed consent [+2]

Status: Recruiting

iTBS to Enhance Social Cognition in People With Psychosis

The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychotic disorder not otherwise specified. The main objectives of this trial are: * Compare changes in social cognitive performance between the active vs. sham treatment groups * Compare changes in social cognitive network functional connectivity between the active vs. sham treatment groups Each participant will receive iTBS (active or sham) five days per week for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at pre-treatment, post-treatment, and 6 months after the completion of treatment.

Participants needed: 100
Trial details
Age: 18-39Biological sex: AllType: InterventionalSponsor: Northwell HealthUpdated: May 22, 2025Locations: 1
Eligibility criteria

Age 18-39 years. [+3]

A history of a DSM-5 substance use disorder (other than cannabis, caffeine, or t... [+9]